OTCMKTS:TLOG

TetraLogic Pharmaceuticals Competitors

$0.04
-0.01 (-16.48 %)
(As of 04/14/2021 03:30 PM ET)
Add
Compare
Today's Range
$0.03
Now: $0.04
$0.05
50-Day Range
$0.04
MA: $0.05
$0.06
52-Week Range
$0.01
Now: $0.04
$0.06
Volume16,485 shs
Average Volume34,349 shs
Market Capitalization$928,875.00
P/E RatioN/A
Dividend YieldN/A
Beta1.38

Competitors

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) Vs. AMBS, AKRXQ, IMNPQ, VGLS, INNVD, and RSPI

Should you be buying TLOG stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to TetraLogic Pharmaceuticals, including Amarantus BioScience (AMBS), Akorn (AKRXQ), Immune Pharmaceuticals (IMNPQ), VG Life Sciences (VGLS), Innovus Pharmaceuticals (INNVD), and RespireRx Pharmaceuticals (RSPI).

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and Amarantus BioScience (OTCMKTS:AMBS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, valuation and earnings.

Analyst Recommendations

This is a breakdown of current ratings and price targets for TetraLogic Pharmaceuticals and Amarantus BioScience, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TetraLogic Pharmaceuticals0000N/A
Amarantus BioScience0000N/A

Volatility and Risk

TetraLogic Pharmaceuticals has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, Amarantus BioScience has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are held by institutional investors. 15.4% of TetraLogic Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of Amarantus BioScience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares TetraLogic Pharmaceuticals and Amarantus BioScience's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A
Amarantus BioScienceN/AN/AN/AN/AN/A

Profitability

This table compares TetraLogic Pharmaceuticals and Amarantus BioScience's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TetraLogic PharmaceuticalsN/AN/AN/A
Amarantus BioScienceN/AN/AN/A

Summary

TetraLogic Pharmaceuticals beats Amarantus BioScience on 2 of the 3 factors compared between the two stocks.

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, analyst recommendations, institutional ownership and risk.

Profitability

This table compares TetraLogic Pharmaceuticals and Akorn's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TetraLogic PharmaceuticalsN/AN/AN/A
Akorn-54.01%-5.13%-0.49%

Analyst Ratings

This is a breakdown of current ratings and target prices for TetraLogic Pharmaceuticals and Akorn, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TetraLogic Pharmaceuticals0000N/A
Akorn0000N/A

Risk and Volatility

TetraLogic Pharmaceuticals has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Valuation and Earnings

This table compares TetraLogic Pharmaceuticals and Akorn's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A
Akorn$682.43 million0.01$-226,770,000.00N/AN/A

TetraLogic Pharmaceuticals has higher earnings, but lower revenue than Akorn.

Institutional and Insider Ownership

0.1% of Akorn shares are held by institutional investors. 15.4% of TetraLogic Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of Akorn shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

TetraLogic Pharmaceuticals beats Akorn on 5 of the 7 factors compared between the two stocks.

Immune Pharmaceuticals (OTCMKTS:IMNPQ) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Immune Pharmaceuticals and TetraLogic Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Immune PharmaceuticalsN/AN/AN/A
TetraLogic PharmaceuticalsN/AN/AN/A

Risk and Volatility

Immune Pharmaceuticals has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Earnings and Valuation

This table compares Immune Pharmaceuticals and TetraLogic Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immune PharmaceuticalsN/AN/AN/AN/AN/A
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations for Immune Pharmaceuticals and TetraLogic Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Immune Pharmaceuticals0000N/A
TetraLogic Pharmaceuticals0000N/A

Summary

TetraLogic Pharmaceuticals beats Immune Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and VG Life Sciences (OTCMKTS:VGLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Profitability

This table compares TetraLogic Pharmaceuticals and VG Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TetraLogic PharmaceuticalsN/AN/AN/A
VG Life SciencesN/AN/AN/A

Risk and Volatility

TetraLogic Pharmaceuticals has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, VG Life Sciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for TetraLogic Pharmaceuticals and VG Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TetraLogic Pharmaceuticals0000N/A
VG Life Sciences0000N/A

Valuation and Earnings

This table compares TetraLogic Pharmaceuticals and VG Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A
VG Life SciencesN/AN/AN/AN/AN/A

Summary

VG Life Sciences beats TetraLogic Pharmaceuticals on 1 of the 1 factors compared between the two stocks.

Innovus Pharmaceuticals (OTCMKTS:INNVD) and TetraLogic Pharmaceuticals (OTCMKTS:TLOG) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Institutional and Insider Ownership

10.4% of Innovus Pharmaceuticals shares are held by institutional investors. 16.4% of Innovus Pharmaceuticals shares are held by insiders. Comparatively, 15.4% of TetraLogic Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Innovus Pharmaceuticals and TetraLogic Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innovus Pharmaceuticals0000N/A
TetraLogic Pharmaceuticals0000N/A

Profitability

This table compares Innovus Pharmaceuticals and TetraLogic Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innovus Pharmaceuticals-34.51%-682.54%-78.57%
TetraLogic PharmaceuticalsN/AN/AN/A

Risk and Volatility

Innovus Pharmaceuticals has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500. Comparatively, TetraLogic Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.

Earnings & Valuation

This table compares Innovus Pharmaceuticals and TetraLogic Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innovus Pharmaceuticals$23.99 million0.00$-8,280,000.00($4.16)N/A
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A

TetraLogic Pharmaceuticals has lower revenue, but higher earnings than Innovus Pharmaceuticals.

Summary

Innovus Pharmaceuticals beats TetraLogic Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

TetraLogic Pharmaceuticals (OTCMKTS:TLOG) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for TetraLogic Pharmaceuticals and RespireRx Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TetraLogic Pharmaceuticals0000N/A
RespireRx Pharmaceuticals0000N/A

Risk & Volatility

TetraLogic Pharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, RespireRx Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Valuation & Earnings

This table compares TetraLogic Pharmaceuticals and RespireRx Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TetraLogic PharmaceuticalsN/AN/AN/AN/AN/A
RespireRx PharmaceuticalsN/AN/A$-2,120,000.00N/AN/A

Profitability

This table compares TetraLogic Pharmaceuticals and RespireRx Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TetraLogic PharmaceuticalsN/AN/AN/A
RespireRx PharmaceuticalsN/AN/A-3,387.16%

Summary

TetraLogic Pharmaceuticals beats RespireRx Pharmaceuticals on 2 of the 2 factors compared between the two stocks.


TetraLogic Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AMBS
Amarantus BioScience
0.0$0.01-1.8%$4.13 millionN/A0.00Increase in Short Interest
AKRXQ
Akorn
0.1$0.03-0.0%$3.60 million$682.43 million-0.01
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.17-12.1%$3.47 millionN/A0.00High Trading Volume
Increase in Short Interest
News Coverage
Gap Up
VG Life Sciences logo
VGLS
VG Life Sciences
0.0$0.01-1.3%$3.45 millionN/A0.00Increase in Short Interest
News Coverage
INNVD
Innovus Pharmaceuticals
0.6N/AN/A$2.90 million$23.99 million-0.72Gap Down
RSPI
RespireRx Pharmaceuticals
0.5$0.04-0.0%$2.84 millionN/A-0.09
NSPX
Inspyr Therapeutics
0.5$0.02-0.0%$2.31 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.02-0.0%$2.16 million$20,000.00-0.97News Coverage
Gap Up
VVUSQ
VIVUS
0.6$0.12-0.0%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.48-6.2%$2.01 millionN/A0.00
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$36.01-5.6%$1.95 million$2 million0.00High Trading Volume
Gap Down
WWHC
W World
0.8$6.09-0.0%$1.80 millionN/A0.00Increase in Short Interest
News Coverage
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.51-5.9%$1.80 millionN/A0.00Gap Up
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03-21.6%$1.70 million$530,000.000.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.00-5.0%$1.67 million$710,000.000.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.02-50.0%$1.52 millionN/A0.00Gap Up
MLNTQ
Melinta Therapeutics
0.2$0.11-0.0%$1.51 million$96.43 million0.00
Achaogen logo
AKAOQ
Achaogen
0.6$0.03-0.4%$1.31 million$8.73 million0.00Gap Up
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05-0.0%$1.12 millionN/A-0.57High Trading Volume
Decrease in Short Interest
News Coverage
AOLS
Aeolus Pharmaceuticals
0.8$0.01-0.0%$1.07 millionN/A0.00Increase in Short Interest
News Coverage
Gap Up
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.21-4.8%$1.03 millionN/A0.00Decrease in Short Interest
Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07-2.1%$970,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
SPHS
Sophiris Bio
0.1$0.03-0.0%$965,000.00N/A0.00Increase in Short Interest
News Coverage
Gap Up
ATRX
Adhera Therapeutics
0.0$0.08-0.0%$872,000.00$250,000.000.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01-125.0%$772,000.00N/A0.00Gap Up
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.02-36.3%$749,000.00N/A0.00News Coverage
Gap Up
PXYN
Praxsyn
0.6$0.00-20.0%$678,000.00N/A0.00Increase in Short Interest
Gap Down
SKVI
Skinvisible
0.7$0.15-0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05-0.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$9.15-1.0%$458,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.17-0.0%$436,000.00N/A0.00
HSTC
HST Global
0.8$0.07-0.0%$378,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47-3.7%$338,000.00$36.55 million0.00News Coverage
Gap Up
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.01-0.0%$319,000.00N/A0.00Increase in Short Interest
Gap Down
PZRXQ
PhaseRx
0.2$0.03-0.0%$298,000.00N/A0.00Decrease in Short Interest
News Coverage
WDBG
Woodbrook Group
0.0$1.60-0.0%$224,000.00N/A0.00
ROSGQ
Rosetta Genomics
0.0$0.09-5.9%$124,000.00N/A0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.02-0.0%$118,000.00$20,000.000.00
OREXQ
Orexigen Therapeutics
0.4$0.01-26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00-0.0%$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00-0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00-0.0%$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.02-0.0%$8,000.00$110,000.000.00Decrease in Short Interest
Acusphere logo
ACUS
Acusphere
0.0$0.05-26.2%$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.09-13.6%$0.00N/A0.00Gap Down
AOBI
American Oriental Bioengineering
0.4$1.50-0.0%$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01-1.4%$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01-0.0%$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07-0.1%$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01-0.0%$0.00N/A0.00
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.